Effects of chitosan-stabilized selenium nanoparticles on cell proliferation, apoptosis and cell cycle pattern in HepG2 cells: Comparison with other selenospecies

Colloids and Surfaces B: Biointerfaces

Volumn 122, Issue , 2014, Pages 184-193

  Estevez, Hector ^a   Garcia Lidon, J Carlos ^a   Luque Garcia, Jose L ^a   Camara, Carmen ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cdk1 targeting compounds; Cell cycle arrest; Chitosan stabilized selenium nanoparticles; Selenocompounds

Indexed keywords

CELL DEATH; CELL PROLIFERATION; CHITOSAN; NANOPARTICLES; SELENIUM;

ANTIOXIDANT PROPERTIES; BIOLOGICAL FUNCTIONS; CDK1-TARGETING COMPOUNDS; CELL-CYCLE ARREST; CHEMOTHERAPEUTIC AGENTS; FUTURE APPLICATIONS; SELENIUM NANOPARTICLES; SELENOCOMPOUNDS; CELL CYCLE; HEP-G2 CELLS;

SELENIUM COMPOUNDS;

ANTINEOPLASTIC AGENT; CHITOSAN; NANOPARTICLE; SELENIUM; SELENIUM NANOPARTICLE; SELENO METHYLSELENOCYSTEINE; SELENOCYSTINE; SELENOMETHIONINE; UNCLASSIFIED DRUG; METAL NANOPARTICLE; CYCLIN DEPENDENT KINASE 1; SELENATE; SELENOAMINO ACID; SELENOMETHYLSELENOCYSTEINE; SODIUM SELENITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; CHEMISTRY; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; MITOSIS; TRANSMISSION ELECTRON MICROSCOPY;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CHITOSAN; HEP G2 CELLS; HUMANS; METAL NANOPARTICLES; SELENIUM;

EID: 84904390043     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.06.062     Document Type: Article

References (38)

1. Fairweather-Tait S.K., Bao Y., Broadley M.R., Collings R., Ford D., Hesketh J.E., Hurst R. Selenium in human health and disease. Antioxid. Redox Signal. 2011, 14:1337-1383.
2. Rayman M.P. Selenium and human health. Lancet 2012, 379:1256-1268.
3. Ip C., Thompson H.J., Zhu Z., Ganther H.E. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res. 2000, 60:2882-2886.
4. Li G.X., Lee H.J., Wang Z., Hu H., Liao J.D., Watts J.C., Combs G.F., Lu J. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008, 29:1005-1012.
5. Whanger P.D. Selenium and its relationship to cancer: an update. Br. J. Nutr. 2004, 91:11-28.
6. Brozmanová J., Mániková D., Vlcková V., Chovanec M. Selenium: a double-edged sword for defense and offence in cancer. Arch. Toxicol. 2010, 84:919-938.
7. Cassidy P.B., Fain H.D., Cassidy J.P., Tran S.M., Moos P.J., Boucher K.M., Gerads R., Florell S.R., Grossman D., Leachman S.A. Selenium for the prevention of cutaneous melanoma. Nutrients 2013, 5:725-749.
8. Che Y.C., Prabhu K.S., Mastro A.M. Is selenium a potential treatment for cancer metastasis?. Nutrients 2013, 5:1149-1168.
9. Sinha R., El-Bayoumy K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr. Cancer Drug Targets 2004, 4:13-28.
10. Abdulah R., Miyazaki K., Nakazawa M., Koyama H. Chemical forms of selenium for cancer prevention. J. Trace Elem. Med. Biol. 2005, 19:141-150.
11. Shen C.L., Song W., Pence B.C. Interactions of selenium compounds with other antioxidants in DNA damage and apoptosis in human normal keratinocytes. Cancer Epidemiol. Biomarkers Prevent. 2001, 10:385-390.
12. Ferguson L.R., Karunasinghe N., Zhu S., Wang A.H. Selenium and its' role in the maintenance of genomic stability. Mutat. Res. 2012, 733:100-110.
13. Jung H.J., Kim H.L., Kim Y.J., Weon J.I., Seo Y.R. A novel chemopreventive mechanism of selenomethionine: enhancement of APE1 enzyme activity via Gadd45a, PCNA and APE1 protein complex that regulates p53-mediated base excision repair. Oncol. Rep. 2013, 30:1581-1586.
14. Luque-Garcia J.L., Sanchez-Diaz R., Lopez-Heras I., Martin P., Camara C. Bioanalytical strategies for in-vitro and in-vivo evaluation of the toxicity induced by metallic nanoparticles. Trends Anal. Chem. 2013, 43:254-268.
15. Zhang J., Wang X., Xu T. Elemental selenium at nano size (Nano-Se) as a potential chemopreventive agent with reduced risk of selenium toxicity: comparison with se-methylselenocysteine in mice. Toxicol. Sci. 2008, 101:22-31.
16. Wang H., Zhang J., Yu H. Elemental selenium at nano size possesses lower toxicity without compromising the fundamental effect on selenoenzymes: comparison with selenomethionine in mice. Free Radical Biol. Med. 2007, 42:1524-1533.
17. Zhang J.S., Gao X.Y., Zhang L.D., Bao Y.P. Biological effects of a nano red elemental selenium. Biofactors 2001, 15:27-38.
18. Chen T., Wong Y.S., Zheng W., Bai Y., Huang L. Selenium nanoparticles fabricated in Undaria pinnatifida polysaccharide solutions induce mitochondria-mediated apoptosis in A375 human melanoma cells. Colloids Surf., B: Biointerfaces 2008, 67:26-31.
19. Huang Y., He L., Liu W., Fan C., Zheng W., Wong Y.S., Chen T. Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles. Biomaterials 2013, 34:7106-7116.
20. Wu H., Zhu H., Li X., Li Z., Zheng W., Chen T., Yu B., Wong K.H. Induction of apoptosis and cell cycle arrest in A549 human lung adenocarcinoma cells by surface-capping selenium nanoparticles: an effect enhanced by polysaccharide-protein complexes from Polyporus rhinocerus. J. Agric. Food Chem. 2013, 61:9859-9866. 10.1021/jf403564s.
21. Luo H., Wang F., Bai Y., Chen T., Zheng W. Selenium nanoparticles inhibit the growth of HeLa and MDA-MB-231 cells through induction of S phase arrest. Colloids Surf., B: Biointerfaces 2012, 94:304-308.
22. Kim J.A., Aberg C., Salvati A., Dawson K.A. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat. Nanotechnol. 2011, 7:62-68.
23. Mahmoudi M., Azadmanesh K., Shokrgozar M.A., Journeay W.S., Laurent S. Effect of nanoparticles on the cell life cycle. Chem. Rev. 2011, 111:3407-3432.
24. Bai Y., Wang Y., Zhou Y., Li W., Zheng W. Modification and modulation of saccharides on elemental selenium nanoparticles in liquid phase. Mater. Lett. 2008, 62:2311-2314.
25. Luo Y., Zhang B., Cheng W.H., Wang Q. Preparation, characterization and evaluation of selenite-loaded chitosan/TPP nanoparticles with or without zein coating. Carbohydr. Polym. 2010, 82:942-951.
26. Zhang S., Luo Y., Zeng H., Wang Q., Tian F., Song J., Cheng W.H. Encapsulation of selenium in chitosan nanoparticles improves selenium availability and protects cells from selenium-induced DNA damage response. J. Nutr. Biochem. 2011, 22:1137-1142.
27. Zhong W., Oberley T.D. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res. 2001, 61:7071-7078.
28. Králová V., Benesová S., Cervinka M., Rudolf E. Selenite-induced apoptosis and autophagy in colon cancer cells. Toxicol. In Vitro 2012, 26:258-268.
29. Li Z., Meng J., Xu T.J., Qin X.Y., Zhou X.D. Sodium selenite induces apoptosis in colon cancer cells via Bax-dependent mitochondrial pathway. Eur. Rev. Med. Pharmacol. Sci. 2013, 17:2166-2171.
30. Malumbres M. Physiological relevance of cell cycle kinases. Physiol. Rev. 2011, 91:973-1007.
31. Malumbres M., Barbacid M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 2007, 17:60-65.
32. Malumbres M., Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 2005, 30:630-641.
33. Manchado E., Guillamot M., Malumbres M. Killing cells by targeting mitosis. Cell Death Differ. 2012, 19:369-377.
34. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006, 24:1770-1783.
35. Zeng H. Selenite and selenomethionine promote HL-60 cell cycle progression. J. Nutr. 2002, 132:674-679.
36. Ganther H.E. Selenium metabolims, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999, 20:1657-1666.
37. Malumbres M., Pevarello P., Barbacid M., Bischoff J.R. CDK inhibitors in cancer therapy: what is next. Trends Pharmacol. Sci. 2008, 29:16-21.
38. Lee K., Kenny A.E., Rieder C.L. Caspase activity is not required for the mitotic checkpoint or mitotic slippage in human cells. Mol. Biol. Cell 2011, 22:2470-2479.